HIV-1整合酶链转移抑制剂的比较临床药代动力学与药效学:更新综述
本文综述了比克替拉韦、卡博特韦、多替拉韦、埃替拉韦和拉替拉韦五种HIV整合酶链转移抑制剂的药代动力学与药效学特性。这些药物对HIV整合酶有强效抑制作用,IC90/95值在低纳克每毫升级别,并保留对其他抗逆转录病毒药物耐药株的活性。各药物因代谢途径不同而具有独特的药物相互作用特征,文章还描述了肝肾功能不全、妊娠和合并感染等特殊人群的药代动力学考虑。
要点
- 卡博特韦、拉替拉韦和多替拉韦的代谢极少涉及细胞色素P450,药物相互作用较少。
- 埃替拉韦主要经CYP3A4代谢,需药代动力学增强剂以实现每日一次给药。
- 比克替拉韦、多替拉韦和拉替拉韦被美国成人及青少年HIV治疗指南推荐为初始方案组分。
核心结论
- 整合酶链转移抑制剂各具独特药代动力学/药效学特性,影响其在特定患者亚群中的临床定位。
研究设计与样本
- 综述比较了比克替拉韦、卡博特韦、多替拉韦、埃替拉韦和拉替拉韦的药代动力学与药效学,并描述肝损伤、肾功能不全、妊娠和合并感染者的药代动力学考虑。
主要发现
- 整合酶链转移抑制剂对HIV整合酶的IC90/95值在低纳克每毫升级别,且对耐其他类抗逆转录病毒药物的HIV株保留抗病毒活性。
- 卡博特韦有口服和肌内注射剂型,肌内注射长效缓释剂型已显示疗效。
- 卡博特韦、拉替拉韦和多替拉韦因代谢极少涉及细胞色素P450而药物相互作用谱较窄。
- 埃替拉韦代谢主要经细胞色素P450 3A4,需药代动力学增强以实现每日一次给药的全身暴露。
- 比克替拉韦代谢由细胞色素P450 3A4和尿苷5'-二磷酸-葡萄糖醛酸转移酶1A1共同参与。
关键数值与推荐
- 比克替拉韦、多替拉韦和拉替拉韦是美国成人及青少年HIV治疗指南推荐的初始方案组分。
- 卡博特韦已在加拿大获批,但尚未获美国食品药品监督管理局批准。
临床怎么用
- 临床选用整合酶链转移抑制剂时应考虑各药物的代谢途径差异及由此产生的药物相互作用风险。
- 对肝损伤、肾功能不全、妊娠和合并感染患者需结合特定药代动力学考虑调整用药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bictegravir, cabotegravir, dolutegravir, elvitegravir, and raltegravir are members of the latest class of antiretrovirals available to treat human immunodeficiency virus (HIV) infection, the integrase strand transfer inhibitors. Integrase strand transfer inhibitors are potent inhibitors of the HIV integrase enzyme with IC90/95 values in the low nanogram per milliliter range and they retain antiviral activity against strains of HIV with acquired resistance to other classes of antiretrovirals. Each of the integrase strand transfer inhibitors have unique pharmacokinetic/pharmacodynamic properties, influencing their role in clinical use in specific subsets of patients. Cabotegravir, approved for use in Canada but not yet by the US Food and Drug Administration, is formulated in both oral and intramuscular formulations; the latter of which has shown efficacy as a long-acting extended-release formulation. Cabotegravir, raltegravir, and dolutegravir have minimal drug-drug interaction profiles, as their metabolism has minimal cytochrome P450 involvement. Conversely, elvitegravir metabolism occurs primarily via cytochrome P450 3A4 and requires pharmacokinetic boosting to achieve systemic exposures amenable to once-daily dosing. Bictegravir metabolism has similar contributions from both cytochrome P450 3A4 and uridine 5'-diphospho-glucuronosyltransferase 1A1. Bictegravir, dolutegravir, and raltegravir are recommended components of initial regimens for most people with HIV in the US adult and adolescent HIV treatment guidelines. This review summarizes and compares the pharmacokinetics and pharmacodynamics of the integrase strand transfer inhibitor agents, and describes specific pharmacokinetic considerations for persons with hepatic impairment, renal dysfunction, pregnancy, and co-infections.
引用
- Podany AT, Scarsi KK, Pham MM, et al. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review. Clin Pharmacokinet. 2020. PMID: 32462541. doi:10.1007/s40262-020-00898-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。